A friend of Biocurex has educated me on the fact that point of care testing has the fastest growth and better margins for diagnostics and is simpler to administer and will be future of medicine. The analyzers add to expense and are more complicated and results may take longer and most importantly the margins are lower. Bottom line is that money talks.

Abbott has lead us to Inverness (a Godsend) which is one of, if not the most experienced and agressive leaders in point of care testing. Blood, saliva, and urine point of care. We sold a radioactive labeled recaf test to Abbott then transformed it into a chemoluminescent test then an Elisa now rapid test in the blink of an eye. Things that were only an aspiration or just a theory have developed into a reality. I have to believe that Inverness is more than impressed with Dr Moro's ability to deliver. Now let's transform recaf into a printing press and let's start printing some money.